Casirivimab and imdevimab for the treatment of hospitalized patients with COVID-19
Selin Somersan-Karakaya, Eleftherios Mylonakis, Vidya P. Menon, Jason C. Wells, Shazia Ali, Sumathi Sivapalasingam, Yiping Sun, Rafia Bhore, Jingning Mei, Jutta Miller, Lisa Cupelli, Andrea T. Hooper, Jennifer D. Hamilton, Cynthia Pan, Viet Pham, Yuming Zhao, Romana Hosain, Adnan Mahmood, John D. Davis, Kenneth C. Turner, Yunji Kim, Amanda Cook, Bari Kowal, Yuhwen Soo, A. Thomas DiCioccio, Gregory P. Geba, Neil Stahl, Leah Lipsich, Ned Braunstein, Gary A. Herman, George D. Yancopoulos, David M. Weinreich, COVID-19 Phase 2/3 Hospitalized Trial Team
doi: https://doi.org/10.1101/2021.11.05.21265656
Selin Somersan-Karakaya
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Eleftherios Mylonakis
2Brown University, Providence, RI, USA
Vidya P. Menon
3NYC Health + Hospitals/Lincoln, The Bronx, NY, USA
Jason C. Wells
4The Oregon Clinic, Portland, OR, USA
Shazia Ali
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Sumathi Sivapalasingam
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Yiping Sun
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Rafia Bhore
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Jingning Mei
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Jutta Miller
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Lisa Cupelli
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Andrea T. Hooper
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Jennifer D. Hamilton
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Cynthia Pan
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Viet Pham
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Yuming Zhao
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Romana Hosain
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Adnan Mahmood
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
John D. Davis
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Kenneth C. Turner
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Yunji Kim
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Amanda Cook
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Bari Kowal
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Yuhwen Soo
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
A. Thomas DiCioccio
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Gregory P. Geba
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Neil Stahl
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Leah Lipsich
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Ned Braunstein
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Gary A. Herman
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
George D. Yancopoulos
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
David M. Weinreich
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Data Availability
Qualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, and statistical analysis plan) that support the methods and findings reported in this manuscript. Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification. Submit requests to https://vivli.org/.
Posted January 27, 2022.
Casirivimab and imdevimab for the treatment of hospitalized patients with COVID-19
Selin Somersan-Karakaya, Eleftherios Mylonakis, Vidya P. Menon, Jason C. Wells, Shazia Ali, Sumathi Sivapalasingam, Yiping Sun, Rafia Bhore, Jingning Mei, Jutta Miller, Lisa Cupelli, Andrea T. Hooper, Jennifer D. Hamilton, Cynthia Pan, Viet Pham, Yuming Zhao, Romana Hosain, Adnan Mahmood, John D. Davis, Kenneth C. Turner, Yunji Kim, Amanda Cook, Bari Kowal, Yuhwen Soo, A. Thomas DiCioccio, Gregory P. Geba, Neil Stahl, Leah Lipsich, Ned Braunstein, Gary A. Herman, George D. Yancopoulos, David M. Weinreich, COVID-19 Phase 2/3 Hospitalized Trial Team
medRxiv 2021.11.05.21265656; doi: https://doi.org/10.1101/2021.11.05.21265656
Casirivimab and imdevimab for the treatment of hospitalized patients with COVID-19
Selin Somersan-Karakaya, Eleftherios Mylonakis, Vidya P. Menon, Jason C. Wells, Shazia Ali, Sumathi Sivapalasingam, Yiping Sun, Rafia Bhore, Jingning Mei, Jutta Miller, Lisa Cupelli, Andrea T. Hooper, Jennifer D. Hamilton, Cynthia Pan, Viet Pham, Yuming Zhao, Romana Hosain, Adnan Mahmood, John D. Davis, Kenneth C. Turner, Yunji Kim, Amanda Cook, Bari Kowal, Yuhwen Soo, A. Thomas DiCioccio, Gregory P. Geba, Neil Stahl, Leah Lipsich, Ned Braunstein, Gary A. Herman, George D. Yancopoulos, David M. Weinreich, COVID-19 Phase 2/3 Hospitalized Trial Team
medRxiv 2021.11.05.21265656; doi: https://doi.org/10.1101/2021.11.05.21265656
Subject Area
Subject Areas
- Addiction Medicine (386)
- Allergy and Immunology (701)
- Anesthesia (193)
- Cardiovascular Medicine (2859)
- Dermatology (244)
- Emergency Medicine (431)
- Epidemiology (12569)
- Forensic Medicine (10)
- Gastroenterology (807)
- Genetic and Genomic Medicine (4447)
- Geriatric Medicine (402)
- Health Economics (716)
- Health Informatics (2856)
- Health Policy (1050)
- Hematology (376)
- HIV/AIDS (893)
- Medical Education (415)
- Medical Ethics (114)
- Nephrology (464)
- Neurology (4201)
- Nursing (223)
- Nutrition (617)
- Oncology (2205)
- Ophthalmology (626)
- Orthopedics (254)
- Otolaryngology (319)
- Pain Medicine (269)
- Palliative Medicine (83)
- Pathology (488)
- Pediatrics (1172)
- Primary Care Research (483)
- Public and Global Health (6787)
- Radiology and Imaging (1494)
- Respiratory Medicine (902)
- Rheumatology (430)
- Sports Medicine (369)
- Surgery (473)
- Toxicology (57)
- Transplantation (202)
- Urology (174)